In Vitro and In Vivo Evaluation of Osteogenesis of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells on Partially Demineralized Bone Matrix
In Vitro and In Vivo Evaluation of Osteogenesis of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells on Partially Demineralized Bone Matrix
复制标题
DOI：
10.1089/ten.tea.2009.0516
复制
发表时间：
2010-03-01
影响因子：
4.1
通讯作者：
Cao, Yilin
中科院分区：
文献类型：
--
作者：
Liu, Guangpeng;Li, Yulin;Cao, Yilin
脐带血来源的间充质干细胞（UCB-MSCs）的成骨分化潜能已被证实，部分脱钙骨基质（pDBM）是骨组织工程支架材料的理想候选材料。在这项研究中，从猪松质骨衍生的pDBM支架的能力，以支持人脐血间充质干细胞在体外成骨分化和骨形成能力在体内评估的潜在用途的脐血间充质干细胞在骨组织工程应用进行了评估。从足月人脐带血中分离出间充质干细胞并扩增，分析其细胞表面抗原标记物和分化成成骨细胞、软骨细胞和脂肪细胞的多谱系能力。体外观察人脐血间充质干细胞在pDBM三维支架上的增殖和成骨分化情况。在无胸腺大鼠顶骨双侧形成临界尺寸的全层圆形缺损（直径5 mm），采用以下方法之一进行处理：成骨诱导的UCB-MSC/pDBM复合材料（A组，n = 8），未诱导的UCB-MSC/pDBM复合材料（B组，n = 8），单独的pDBM（C组，n = 8），或不处理（D组，n - 8）。显微计算机断层扫描显示，A组在植入后6周有新骨形成，12周后发现骨体积和密度更大。其他组6周后新骨形成不明显，12周时无骨愈合。组织学检查显示，12周时A组缺损已被组织工程骨修复，B、C和D组均观察到纤维愈合。这些结果表明，pDBM可以支持人UCB-MSCs在体外和体内的成骨分化，和UCB-MSCs可能作为骨组织工程和再生的替代细胞来源。
The osteogenic differentiation potential of umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) has been documented previously, and partially demineralized bone matrix (pDBM) represents a promising candidate for bone tissue engineering scaffolds. In this study, pDBM scaffolds derived from porcine cancellous bone were evaluated for their ability to support human UCB-MSCs osteogenic differentiation in vitro and bone-forming capacity in vivo to assess the potential use of UCB-MSCs in bone tissue engineering applications. MSCs were isolated from full-term human UCB and expanded, and their cell surface antigen markers and multilineage capability to differentiate into osteoblasts, chondrocytes, and adipocytes were analyzed. The in vitro proliferation and osteogenic differentiation of UCB-MSCs loaded onto the three-dimensional pDBM scaffolds were determined. Critical-sized full-thickness circular defects (5 mm in diameter) created bilaterally in the parietal bones of athymic rats were treated with one of the following: osteogenically induced UCB-MSC/pDBM composites (Group A, n = 8), noninduced UCB-MSC/pDBM composites (Group B, n = 8), pDBM alone (Group C, n = 8), or left untreated (Group D, n - 8). Microcomputed tomography analysis showed that new bone was formed in Group A at 6 weeks postimplantation, and greater bone volume and density were found after 12 weeks. In other groups, new bone formation was not evident after 6 weeks, and no bone union was found at 12 weeks. Histological examination revealed that the defect was repaired by tissue-engineered bone in Group A at 12 weeks, and fibrous union was observed in Groups B, C, and D. These results demonstrate that pDBM can support osteogenic differentiation of human UCB-MSCs in vitro and in vivo, and UCB-MSCs may serve as an alternative cell source for bone tissue engineering and regeneration.